Molecular mechanisms of lymphangiogenesis in health and disease.

By K. Alitalo, Peter Carmeliet. Cancer Cell, 2002

709 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/18a6d91a899da130ec5c8e0dce91ef1d48f2f4d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. (2013, background): “From the 1980s to the present, the VEGF-VEGFR system has been demonstrated to be the major regulator of tumor angiogenesis (2-4) (Fig.”
Molecular regulation of vessel maturation (2003, background): “Molecular approaches have confirmed this notion in recent years, and have suggested additional sources of lymphatic EC”
Vascular Endothelial Growth Factor and Angiogenesis (2004, background): “However, caution is warranted, since destruction of the lymphatic vessels could elevate the already increased interstitial fluid pressure inside the tumor, thereby further impairing the delivery of other anticancer drugs (Alitalo and Carmeliet, 2002).”
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. (2004, background): “hemangiogenic properties (2, 9, 10, 36, 37), and VEGFR3, while universally expressed by the lymphatic endothelium, is also expressed by vascular endothelial cells under some conditions, particularly during embryonic development and periods of active vessel remodeling, including that occurring in pat”
Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. (2006, background): “VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1), and VEGFR3 (Flt-4) are highly homologous to each other in overall structure (Shibuya et al., 1990; Alitalo and Carmeliet, 2002), and closely related to the PDGF receptor family including PDGFR, CSF-1 receptor (c-Fms), SCF receptor (c-Kit), and Flt3.”
VEGF-targeted therapy: mechanisms of anti-tumour activity (2008, background): “VEGFR3 is important in cardiovascular development and remodelling of primary vascular networks during embryogenesis, and has a crucial role in post-natal lymphangiogenesi”
Targeting of drugs and nanoparticles to tumors (2010, background): “The expression of many of these proteins in tumor vessels is associated with angiogenesis, and they are often functionally important in that process (Hanahan and Folkman, 1996; Alitalo and Carmeliet, 2002).”
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis (2005, background): “Thus far, VEGF-C and VEGF-D are the only known lymphangiogenesis factors—acting predominantly through activation of VEGFR-3—which is expressed by lymphatic endothelium in vivo and in vitro (7).”
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. (2011, background): “VEGF-C–/– mice show severe accumulation of fluid in tissues due to poor development of lymph vessels.(6)”
Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma (2003, background): “Lymphangiogenesis often accompanies angiogenesis, and this field of research is now gaining momentum with new research tool”
Integrin signalling during tumour progression (2004, background): “Lymphatic vessels, on the other hand, lack a continuous basement membrane and TIGHT JUNCTIONS , and so provide an accessible route for cancer cells to spread to regional lymph node”
High interstitial fluid pressure — an obstacle in cancer therapy (2004, background): “Moreover, lymphatic vessels are absent or non-functional in tumour”